... 1,1,1,1,-3,-2,1,2,1,2)) L.6.3. WinBUGS code for inconsistency model for ... 2,0,0,-3,0, 2,1,-1,1,-2, 0)) L.6.10. WinBUGS code for assessment of baseline ...

... C1: Placebo n= 92 C2: Lithium 0.8–1.2 mEq/L (Mean 0.9 mEq/L) n= 90 52 ... C2:Lithium 600–1800 mg/day 0.6–1.2 mEq/L (0.63 mEq/L mean) N=364 104 ... C1: Placebo n= 92 C2: Lithium 0.8–1.2 mEq/L (Mean 0.9 mEq/L) n= 90 52 ...

... 600–900 mg/day serum level 0.6–1.2 mmol/L (mean 0.99 mmol/L) Placebo Lithium 600–900 mg/day serum level 0.6–1.2 mmol/L (mean 0.95 mmol/L) 4 weeks CGI - ... 600–900 mg/day serum level 0.6–1.2 mmol/L (mean 0.99 mmol/L) Placebo Lithium 600– ...

... 2000 mg/day (target serum level 0.6–1.2 mmol/L) (0.80 mmol/L average) 4 weeks MADRS ... Haloperidol 10 mg/day C3: Lithium 0.6–1.2 mmol/L 4 weeks BPRS CGI Unknown Scale - Not reported ...

... caused by pathogenic variants in the Ca V 1.2 L-type calcium channel gene , CACNA1C . Suggestive Findings Diagnosis ... 8 Normal gene product . CACNA1C encodes Ca V 1.2, the cardiac L-type calcium channel, which is important for excitation ...

... multivariable analysis Zhang 2015 618 No multivariable analysis L.1.2. Routine referral Table 71 Studies excluded from the ...

... Not a guideline Wyatt 2014 Not a guideline L.1.2. Barriers of care Table 255 Studies excluded from ...

... other interventions was considered important by the GDG. L.3.1.2. Population The model considered a cohort of patients who had had a recent MI. The baseline characteristics of the patients in the model are ... Q ). L.3.1.3. Time horizon, perspective, discount rates ...